3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
1
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
13
Glioblastoma
4
Brain Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Pancreatic Neoplasms
2
Neoplasms
2
Melanoma
2
Glioma
2
Astrocytoma
2
Urothelial Carcinoma of the Bladder
1
Prostatic Hyperplasia
1
Pathologic Complete Response
1
Paranasal Sinus Neoplasms
1
Oligodendroglioma
1
Non-Muscle Invasive Bladder Urothelial Carcinoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neuroblastoma
1
Nasopharyngeal Carcinoma
1
Muscle-invasive Urothelial Cancer of the Bladder
1
Mouth Neoplasms
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Laryngeal Neoplasms
1
Ganglioneuroblastoma
1
Estrogen Receptor Positive Breast Cancer
1
Ependymoma
1
Craniopharyngioma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Interventions
pembrolizumab
180
Gemcitabine
168
Paclitaxel
150
Carboplatin
134
Bevacizumab
126
Cisplatin
113
Docetaxel
112
Cyclophosphamide
109
Exercise
97
Nivolumab
92
Fluorouracil
88
Capecitabine
85
Dexamethasone
81
Irinotecan
74
Radiotherapy
68
Oxaliplatin
68
Pemetrexed
66
Standard of Care
64
Leucovorin
63
Cetuximab
59
Sorafenib
53
Erlotinib Hydrochloride
53
Drug Therapy
53
Blood Specimen Collection
52
Doxorubicin
50
trametinib
47
atezolizumab
47
Ipilimumab
47
Albumin-Bound Paclitaxel
44
130-nm albumin-bound paclitaxel
42
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms
×
Transurethral Resection of Bladder
×
Clear all
NCT07067749
2025-07-24
TEMPO-MIBC
University of Rome Tor Vergata
Phase 3
Recruiting
92 enrolled
NCT05684874
2023-10-30
SarQuantIRM
Centre Leon Berard
Phase NA
Unknown
25 enrolled